Brexit spells upheaval for EU and UK drug regulation
June 24, 2016 at 07:41 AM EDT
LONDON, June 24 (Reuters) - Britain's vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA), which approves treatments for all EU countries, expected to have to relocate.
